NCT07291232RecruitingPhase 1
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 19 Nov 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- AbbVie
- Diseases
- Obesity
- NCT number
- NCT07291232
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 80
- From 19 Nov 2025 to the primary completion date, Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
- Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
Lab values
- HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
Who the study is looking for
- BMI ≥ 30.0 to ≤ 45.0 kg/m2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with or without weight related stable comorbidities (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CenExel Act- Anaheim Clinical Trials /ID# 283200 Coordinator of this site? Confirm its status | Anaheim | United States | Recruiting |
| Acpru /Id# 278624 Coordinator of this site? Confirm its status | Grayslake | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.